Literature DB >> 453442

The effect of trimethoprim and sulfamethoxazole on Toxoplasma gondii in vitro and in vivo.

P L Grossman, J S Remington.   

Abstract

Trimethoprim (TMP) and sulfamethoxazole (SMZ) were studied alone and in combination to determine their effect in vitro on intracellular Toxoplasma gondii and in vivo against murine toxoplasmosis. In the in vitro experiments, whereas 1 and 2 microgram/ml TMP had no demonstrable effect on intracellular T. gondii, 10-20 microgram/ml TMP resulted in death of the intracellular organisms; concentrations as high as 100 microgram/ml SMZ had no demonstrable effect against the intracellular organisms. When used in combination, a significant synergistic effect was noted with 2 microgram/ml TMP-50 microgram/ml SMZ. Studies on the kinetics of inhibition and/or killing of Toxoplasma revealed that 18 hours of treatment with 2 microgram/ml TMP-50 microgram/ml SMZ resulted in irreversible inhibition of the intracellular organisms. When used in vivo against a 50,000 LD100 dose of Toxoplasma, TMP fed by gavage or mixed in the diet had no effect in murine toxoplasmosis at doses as high as 200 mg/kg a day. SMZ administered by gavage had no effect at doses up to 200 mg/kg a day; but at 300 and 400 mg/kg SMZ, protection was 47% and 83%, respectively. Treatment of infected mice was continued for 14 consecutive days, whether the drugs were administered alone or in combination. The combination 200 mg/kg TMP-200 mg/kg SMZ, when administered by gavage, protected 87% of mice. Survival after 14 days of SMZ mixed in the diet was 0% at 100 mg/kg, 47% at 200 mg/kg, and 100% at 300 mg/kg. Survival with the combination was 40% for 200 mg/kg TMP-100 mg/kg SMZ and 100% for 100 mg/kg TMP-200 mg/kg SMZ. The half-life of TMP in serum of Swiss Webster mice was calculated to be 24 min. The results obtained in vivo were inferior to those obtainable with the combination of pyrimethamine plus sulfadiazine. The problems of interpretation of results obtained in the murine model using TMP-SMZ and in their extrapolation to the treatment of the infection in man are discussed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 453442     DOI: 10.4269/ajtmh.1979.28.445

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  26 in total

Review 1.  ABC of AIDS: treatment of infections and antiviral agents.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1987-09-12

2.  Lipophilic antifolate trimetrexate is a potent inhibitor of Trypanosoma cruzi: prospect for chemotherapy of Chagas' disease.

Authors:  Olga Senkovich; Vandanajay Bhatia; Nisha Garg; Debasish Chattopadhyay
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii.

Authors:  D M Israelski; C Tom; J S Remington
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

Review 4.  Clinically Available Medicines Demonstrating Anti-Toxoplasma Activity.

Authors:  Andrew J Neville; Sydney J Zach; Xiaofang Wang; Joshua J Larson; Abigail K Judge; Lisa A Davis; Jonathan L Vennerstrom; Paul H Davis
Journal:  Antimicrob Agents Chemother       Date:  2015-09-21       Impact factor: 5.191

5.  New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A.

Authors:  D G Mack; R McLeod
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

6.  Concentrations of trimethoprim and sulfamethoxazole in cerebrospinal fluid and serum in mares with and without a dimethyl sulfoxide pretreatment.

Authors:  S L Green; I G Mayhew; M P Brown; R R Gronwall; G Montieth
Journal:  Can J Vet Res       Date:  1990-04       Impact factor: 1.310

7.  Randomized trial of trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine for therapy of toxoplasmic encephalitis in patients with AIDS. Italian Collaborative Study Group.

Authors:  D Torre; S Casari; F Speranza; A Donisi; G Gregis; A Poggio; S Ranieri; A Orani; G Angarano; F Chiodo; G Fiori; G Carosi
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

8.  Thrombospondin-1 null mice are resistant to hypoxia-induced pulmonary hypertension.

Authors:  Cristhiaan D Ochoa; Lunyin Yu; Essam Al-Ansari; Charles A Hales; Deborah A Quinn
Journal:  J Cardiothorac Surg       Date:  2010-05-04       Impact factor: 1.637

9.  In vitro and in vivo effects of doxycycline on Toxoplasma gondii.

Authors:  H R Chang; R Comte; J C Pechère
Journal:  Antimicrob Agents Chemother       Date:  1990-05       Impact factor: 5.191

Review 10.  Human antiprotozoal therapy: past, present, and future.

Authors:  M Khaw; C B Panosian
Journal:  Clin Microbiol Rev       Date:  1995-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.